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Viral respiratory infections including influenza and respiratory syncytial virus (RSV) have been
reported during the Hajj among international pilgrims. To help establish the burden of these
infections at the Hajj, we set up a study to confirm these diagnoses in symptomatic British
pilgrims who attended the 2005 Hajj. UK pilgrims with symptoms of upper respiratory tract
infection (URTI) were invited to participate; after taking medical history, nasal swabs were
collected for point-of-care testing (PoCT) of influenza and for subsequent PCR analysis for
influenza and RSV. Of the 205 patients recruited, 37 (18%) were positive for either influenza or
RSV. Influenza A (H3) accounted for 54% (20/37) of the virus-positive samples, followed by RSV
24% (9/37), influenza B 19% (7/37), and influenza A (H1) 3% (1/37). Of the influenza-positive
cases, 29% (8/28) had recently had a flu immunisation. Influenza was more common in those
who gave a history of contact with a pilgrim with a respiratory illness than those who did not (17
versus 9%). The overall rate of RSV was 4% (9/202). This study confirms that influenza and RSV
cause acute respiratory infections in British Hajj pilgrims. Continuing surveillance and a
programme of interventions to contain the spread of infection are needed at the Hajj,
particularly when the world is preparing for an influenza pandemic.
Introduction
The Hajj is an annual pilgrimage of Muslims in Mecca, the
holiest place of Islam. Every able Muslim is obliged to
perform Hajj at least once in a lifetime, becoming a Hajji.
Annually, more than 2 million Muslims from over 140
countries embark on the Hajj. In the year 2005, about 25,000
Hajjis travelled from the UK alone.
1
Several weeks before the Hajj, pilgrims from different
countries start arriving at various times, in Mecca in groups
usually led by accredited tour operators. At first, they walk
around the Kabah in the Grand Mosque, circling seven times
(Figure 1). Later, some of them go to Medina, a city north of
Mecca, where the shrine of Prophet Mohammed is situated.
On the eighth day of the ‘Hajj Month’ they all move to Mina
in a body and stay there for the next five days in tents
reserved for each tour group by specified country or
continent of origin. Each large tent is shared by 50–100
people. More than 2 million pilgrims move to Arafat for a
day-long stay but come back to Mina after making an
overnight stop in Muzdalifa. Mina, Muzdalifa, and Arafat are
normally uninhabited valleys of 246, 682, and 1361 hectares,
respectively, situated a few miles east of Mecca. Communic-
able diseases resulting from this intense crowding are well
reported.
2
Respiratory illnesses are responsible for most hospital
admissions at the Hajj with pneumonia being the leading
cause.
3 Rapidly transmissible viral respiratory infections, for
example, influenza, have been reported among the pil-
grims.
4–6 Previous estimates suggest that 6% of pilgrims with
URTI have influenza, thus, about 24,000 pilgrims could
suffer from influenza infections during the Hajj each year.
5
Respiratory syncytial virus, a frequent respiratory viral
pathogen in elderly individuals
7 shown to be responsible for
1–3% new respiratory illnesses in symptomatic international
Hajj pilgrims,
4,5 has not been reported previously in British
pilgrims. Hajjis returning home are a source of infection,
This is an Open Access article distributed under the terms of the Creative Commons Attribution licence which permits unrestricted use, distribution,a n d
reproduction in any medium, provided the original work is properly cited.
Emerging Health Threats Journal 2008, 1:e2. doi: 10.3134/ehtj.08.002
& 2008 H Rashid et al.; licensee Emerging Health Threats Journal.
www.eht-journal.orgwhich could give rise to a global influenza outbreak as
demonstrated by the outbreak of meningococcal W135
infection associated with the Hajj in the years 2000 and
2001.
8 Among the European countries, Britain sends most
pilgrims to the Hajj and would be expected to have the
highest risk of infection transmitted by returning Hajj
pilgrims.
9
In this context, our aim was to establish the burden of
influenza and RSV in symptomatic British pilgrims who
attended the Hajj in 2005. We wished to assess the usefulness
of point-of-care testing (PoCT), QuickVue
s influenza test
(Quidel Corporation, San Diego, CA, USA), in guiding
immediate management and compared diagnosis by PoCT
with subsequent analysis of respiratory samples by reverse
transcription polymerase chain reaction (RT-PCR).
Methods
Ethical approval
Multicentre Research Ethics Committee (MREC) approval
was obtained before commencing the study. Initial approval
was for Meningococcal W135 surveillance among Hajj
pilgrims, entitled, ‘Meningococcal W135 carriage; enhanced
surveillance among East London, South London, Mid and
South Buckinghamshire UK Muslims, their household
members and close contacts before and after attending the
Hajj’ in 2002 (Ref: MREC 02/2/12). Amendments were
permitted to cover respiratory infections among Hajj
pilgrims in subsequent years.
Study design
After obtaining informed written consent from each Hajji,
a questionnaire was completed to include demographic
details, presenting symptoms, hospital visits, history of
medication, vaccination history, and risk factors such as
likely contacts, shared accommodation, pre-existing dis-
eases, previous history of Hajj, and smoking. Hajjis were
coded according to their tour groups.
Case definition
UK pilgrims with symptoms of URTI such as sore throat,
cough, runny nose, or fever attending the Hajj in the year
2005.
Study location
The enhanced surveillance was undertaken with the co-
operation of the British Hajj Delegation (BHD) Medical
Clinic and six travel group leaders, which targeted a
population of about 1000. BHD clinic was run by British
general practitioners (GPs) to provide primary medical care
to the pilgrims who were staying in hotel accommodation
around the vicinity of the Grand Mosque in Mecca in the
build up to the Hajj.
The study was carried out in two phases: the first phase was
in Mecca at the BHD clinic near the Grand Mosque on days 1
and 2 of the Hajj and the second in tents in Mina on days 3,
5, 6, and 7. No pilgrim was recruited on day 4, when all
moved to the plain of Arafat for day-long activities as a part
of the ritual.
In the first phase, pilgrims attending the BHD Medical
Clinic were informed about the study and the procedure for
taking samples, and were invited to participate if suffering
from symptoms of URTI.
In the second phase, the team visited each group to
explain the purpose of the study and the procedure
for taking samples. Patients with URTI were invited to
participate.
Pilgrims were examined, temperatures checked, and two
nasal swabs taken.
Those with underlying diseases such as diabetes, chronic
heart, lung, or kidney diseases, otherwise immunosup-
pressed, and those over the age of 65 years old were grouped
as ‘at risk’.
Storage and transport of samples
One of the swabs was used for PoCT and the other was
dipped into lysis buffer (guanidinium thiocyanate and Triton
X-100; Roche Diagnostics, Mannheim, Germany; Code
03246779001) for storage and subsequent transportation to
the UK. Throughout the storage and transportation, a cold
chain of  20 to 41C was maintained.
Patient management
Treatment with oseltamivir was offered to symptomatic
Hajjis who were positive for influenza by PoCT within 48h
of onset of symptoms.
Molecular diagnosis
Molecular diagnosis of influenza and RSV was carried out at
the Centre for Infections at the Health Protection Agency
(London, UK) by RT-PCR as previously described.
10–12
Figure 1 Pilgrims making circumambulations around the Grand Mosque in
Mecca during the Hajj.
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Hajjis were contacted within 12 weeks of the Hajj to
document complications of their viral infections. Vaccina-
tion history was verified by primary care providers.
Data analysis
All statistical analyses were carried out in STATA 9.0. In this
enhanced surveillance study, infections are presented as
proportions tested in the form of percentages. Tests of
significance are Fisher’s exact tests.
Results
Demographic details
We recruited 205 Hajjis with symptoms of URTI, 50% (103/
205) of whom were seen at BHD clinic, and the remaining
102 patients were seen in the Mina tents.
Nasal swabs were collected from 205 patients and 202
samples were analysed (two patients declined to provide
swabs and one sample was lost).
Hajjis came from all over the UK including Northern
Ireland. Ten (5%) non-British Hajjis staying with British
Hajjis were also included in the study. Ninety per cent (185/
205) were men. Ages ranged from 11
2 to 83 years (mean and
median: 44 years). Ethnic origin was 80% Indian (165/205),
5% African (11/205), 2% Arabian (4/205), 1% British (3/205),
6% other (13/205), and 4% unknown (9/205) (Table 1).
Epidemiology and virology
The common presenting symptoms of the Hajjis with URTI
were 80% sore throat (163/205), 74% cough (151/205), 69%
runny nose (142/205), and 53% fever (109/205), whose
positive predictive values for influenza were 92, 82, 75, and
71%, respectively 202.
Nine of 202 (4%) patients were positive for influenza by
PoCT at the time of consultation. All these positive patients
were in the BHD clinic group.
Out of 202 patients, 28 (14%) were positive for influenza
by RT-PCR test, 20 for influenza A H3 (71%), seven for
influenza B (25%), and one for influenza A H1 (4%). PoCT
did not detect the virus in 71% (20/28) of RT-PCR-positive
cases. One PoCT gave a false-positive result (if PCR was
correct), giving a sensitivity and specificity of PoCTas 29 and
99%, and positive and negative predictive values as 89 and
90%, respectively. All other PoCT-positive cases were identi-
fied as influenza A H3 or H1 on PCR testing. All of them
presented four days or more after arrival at the Hajj.
Nine out of the 202 (4%) patients were positive for RSV A
by RT-PCR, and all presented eight days or more after arrival
at the Hajj.
Fifty-eight per cent (118/202) of patients gave a history of
contact with other ill Hajjis, 37% (74/202) gave no history of
contact, and 5% (10/202) were not sure about contact with an
ill pilgrim. The frequency of influenza diagnosis was 17% (20/
118) among those who reported contact with URTI compared
with 9% (7/74) who did not report contact with URTI (P¼0.15).
Sixty (30%) of those with respiratory infection were
treated with antibiotics, the commonly used being amox-
icillin (15%, n¼31), out of which 21 (10%) were in ‘at-risk’
group. Nine (4%) patients were treated with oseltamivir, and
two (1%) were in ‘at-risk’ group.
Vaccination status
Of the 202 patients tested, 56 (28%) received influenza
vaccine before travelling, 143 (71%) definitely did not, and
three (1%) were not sure if they had been vaccinated.
The proportion of influenza-positive cases was 14% (8/56,
20/144) in both vaccinated and unvaccinated patients.
Twenty-nine per cent (8/28) of patients with positive
diagnosis of influenza had confirmed history of vaccination.
‘At-risk’ groups
Twenty-six per cent (53/202) fell into the ‘at-risk’ category, one-
third (n¼18) just because of being aged 465 years. Influenza
vaccine uptake rates were 47% (25/53) in the ‘at-risk’ group and
21% (31/149) in the ‘not at-risk’ group (Po0.01). Confirmed
influenza among ‘at-risk’ and ‘not at-risk’ groups was 9% (5/53)
and 15% (23/149), respectively (P¼0.28) (Table 1). Fifty per
cent (9/18) of pilgrims X65 and 25% (46/184) o65 years of age
were vaccinated. The influenza infection rates in these groups
were 17 and 14%, respectively (P¼0.72).
Fifteen per cent (31/202) of Hajjis reported that they were
regular smokers. Six per cent of smokers (2/31) and 15% of
non-smokers (26/171) tested positive for influenza (P¼0.19).
Post-Hajj follow-up
None of the pilgrims contacted after returning from the Hajj
had complications attributable to influenza or RSV infection.
Table 1 Distribution of influenza and RSV infections among different
categories of patient
Category Sample
size
Influenza-positive
cases (%)
RSV-positive
cases (%)
Ethnicity
Indian 165 19 (12%) 9 (5%)
Arab 4 0 (0%) 0 (0%)
African 11 3 (27%) 0 (0%)
British 3 0 (0%) 0 (0%)
Others 13 6 (46%) 0 (0%)
Unknown 6 0 (0%) 0 (0%)
Age (years)
o16 3 0 (0%) 0 (0%)
16–44 101 17 (17%) 2 (2%)
45–64 80 8 (10%) 5 (6%)
464 18 3 (17%) 2 (11%)
Risk category
At risk 53 5 (9%) 5 (9%)
Not at risk 149 23 (15%) 4 (3%)
Gender
Male 182 23 (13%) 8 (4%)
Female 20 5 (25%) 1 (5%)
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The burden of influenza in the sample of symptomatic
British pilgrims tested at the 2005 Hajj was 14% by RT-PCR
and 4% by PoCT, which compares with 6% found previously
among international pilgrims by virus culture.
5 Influenza A
accounted for 75% (21/28) and influenza B for 25% (7/28) of
positive flu results in this study in contrast to previous
findings of Balkhy et al.,
5 in which 90% (27/30) were found
to have had influenza B and 10% (3/30) influenza A.
Circulating influenza strains differed in the two seasons,
influenza B was predominant in 2003, while influenza A (H3)
was predominant in 2005.
13,14 All patients with influenza
presented four days or more, and all patients with RSV
presented eight days or more after reaching Mecca, suggest-
ing that the infections were acquired at the Hajj.
In this study, the sensitivity of PoCT against RT-PCR was
much lower than in other studies (29% compared with, for
example, 86 and 84%) that had measured its sensitivity
against viral culture,
15,16 although it had a very high
specificity (99%) and positive predictive value. Both the
superiority of RT-PCR, and type and timing of the swab
tested may have influenced the sensitivity of PoCT. Studies
that used nasopharyngeal aspirates or washes (instead of
nose swabs) had generally higher sensitivities, and the
decreasing viral load after the fourth day of symptoms may
reduce PoCT sensitivity.
16,17 Our samples were collected
within one week of onset of symptoms; we could expect
higher sensitivity of the PoCT if all swabs were collected
within four days.
The UK National Institute for Health and Clinical
Excellence recommends that oseltamivir be used as post-
exposure prophylaxis of influenza in at-risk people aged X13
years, who are not effectively protected by immunisation.
18
The logistics of antiviral distribution at the Hajj should be
explored in future studies.
Although it seems that vaccination did not confer
adequate protection against influenza (both groups had the
same rate), it is not possible to draw any conclusion about
vaccine efficacy from this study because the groups were not
comparable; that is, a large number of those immunised were
‘at-risk’ individuals, whereas the majority of those not
immunised were healthy adults, and vaccine failure can
not be ruled out. However, it is likely that there would have
been more confirmed influenza in the British Hajj pilgrims if
none had been vaccinated.
Two previous studies established by virus culture that the
rates of RSV among symptomatic pilgrims were 3 and 1%,
respectively, in 1991–1992 and 2003 Hajj seasons.
4,5 The
slightly higher rate (4%) in our study could be due to
superiority of RT-PCR to virus culture or due to seasonal
variation. Although the proportion of RSV infection at the
Hajj is lower than that of influenza, there is potential for
returning pilgrims to introduce this infection to their
households including children.
19
This study shows the feasibility of enhanced surveillance
at the Hajj and, if strengthened year on year, could help
answer some outstanding questions on the effectiveness of
influenza immunisation, the use of antivirals, and the review
of flu immunisation policy, in comparison with WHO
guidance and the use of influenza vaccine recommended
in Saudi Arabia for Hajj pilgrims.
2
Conclusions
This study confirms influenza and RSV infections among
British Hajj pilgrims and suggests a higher rate than reported
among international pilgrims in previous years. Continuing
and better surveillance at the Hajj is needed, especially now
when an influenza pandemic threatens the world. More
research into the use of antivirals and protective equipment
in such a mixed and crowded setting, preferably prospec-
tively, is also necessary to improve risk assessment and the
effectiveness of interventions.
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